Business Wire

INMARSAT

23.5.2023 09:01:35 CEST | Business Wire | Press release

Share
Inmarsat’s Fastest Ever Inflight Broadband Plans Are Now Available for Business Aviation Customers

Inmarsat has announced the next chapter of its market-leading Jet ConneX (JX) inflight broadband solution, with a new range of service plans introduced to redefine gold standard connectivity in the business aviation market and satisfy even the most data-hungry users for many years to come.

Launched as part of Inmarsat’s JX Evolution programme, these latest service plans are available for new and existing customers to order today, marking a step-change in performance that is backed by guaranteed speeds and Inmarsat’s hallmark consistent customer experience.

The new service plans offer enhanced performance using Jet ConneX’s existing, highly successful JetWave terminal by Inmarsat’s partner Honeywell, and will also be compatible with three upcoming next-generation terminals being developed by Satcom Direct, Orbit and Honeywell. Satcom Direct’s Plane Simple Ka-band system has commenced flight testing and is expected to enter service later this year.

All three next-generation terminals use innovative technology and lightweight designs to optimise performance, reduce costs, and simplify installation and maintenance. Their reduced size and weight make them suitable for various types of business jets, creating new opportunities in the fast-growing super midsize aircraft market, which shares many of the same connectivity requirements as large aircraft.

Jet ConneX customers will also benefit from seven more Inmarsat satellite payloads entering service by 2025, increasing its Ka-band network fleet to 12. This includes two Inmarsat-6s, both of which have already launched, followed by two payloads in highly elliptical orbit, enabling the world’s only commercial mobile broadband service for flights in higher latitudes and across the Arctic. Three additional satellites will then launch in geostationary orbit, adding further speed, capacity, and resilience.

The combination of next generation terminals and Inmarsat’s fast-growing satellite network will enable speeds up to 100 Mbps, for top tier customers that demand the highest level ‘office-in-the-sky’ experience.

The new Jet ConneX service plans are available through Inmarsat’s global business aviation distribution network, which consists of Satcom Direct, Collins Aerospace and Honeywell.

Kai Tang, Inmarsat’s Head of Business Aviation, said “Jet ConneX is renowned for delivering a very high standard of service and these transformative new plans once again highlight Inmarsat’s continued focus on staying ahead of market expectations. This provides customers with reassurance that our connectivity will keep pace with their long-term needs. Importantly, as these include the first plans to use our new satellites and terminals, it also offers a glimpse into future capabilities and provides certainty that their investment in our technology is future-proofed.

“These service plans have been specifically designed to deliver even greater value and performance based on unique insights into usage of our inflight broadband service. This build-up approach is unique to Inmarsat and cannot be replicated by others in the market, some of which have a tendency to over promise and under deliver, either from the start or as their networks fill and performance degrades.

“Crucially, this is only the next step for us. We will continue to assess usage and adapt accordingly, with even more flexible options to be announced later this year.”

Since entering commercial service in November 2016, Jet ConneX has been activated on more than 1,400 business jets: offering the same reliable, consistent and high-speed broadband that was previously only available on the ground. Passenger usage of Jet ConneX increased to record levels since the pandemic, testament to fast-growing expectations from users, who use everything from video streaming and live TV to conference calls and other business activities. JX’s most powerful service plans will now enable passengers to simultaneously connect more devices and enjoy unchallenged access to the most data-hungry applications - including high-definition video conferencing - without compromising on its proven characteristics of consistency, reliability, resilience, and seamless global availability.

Inmarsat’s 2023 global survey of business aviation professionals - conducted in partnership with Corporate Jet Investor (CJI) - found that 82% of respondents believe inflight connectivity has evolved from a luxury option for some, to a key requirement for the majority of passengers. The results, published at the European Business Aviation Convention & Exhibition (EBACE) this week, show the three most important factors when selecting a connectivity system, in order, were consistent performance, 100% route coverage, and high speed.

ENDS

ABOUT INMARSAT
Inmarsat delivers world leading, innovative, advanced and exceptionally reliable global, mobile communications across the world – in the air, at sea and on land - that are enabling a new generation of commercial, government and mission-critical services. Inmarsat is powering the digitalisation of the maritime industry, making operations more efficient and safer than ever before. It is driving a new era of inflight passenger services for aviation, while ensuring that aircraft can fly with maximum efficiency and safety. Furthermore, Inmarsat is enabling the rapid expansion of the Internet of Things (IoT) and enabling the next wave of world-changing technologies that will underpin the connected society and help build a sustainable future. And now Inmarsat is developing the first-of-its-kind, multi-dimensional communications network of the future, ORCHESTRA.

In November 2021, Inmarsat and Viasat announced the planned combination of the two companies, to create a new leader in global communications.

For further information, follow us: Twitter | LinkedIn | Facebook | YouTube | Instagram.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005098/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye